Drugs / Allogeneic NK transfer
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04344548 | Mar → Jun 2020 | COVID-19 | National University of Colombia | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic NK transfer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04344548 ↗ |
| Modality | Cell therapy | “allogeneic NK cells” NCT04344548 ↗ |
| Route | Intravenous | “for intravenous infusion” NCT04344548 ↗ |